Source: https://www.pharmacoeconomics.ru/jour/article/view/144
Timestamp: 2019-04-23 12:03:33+00:00

Document:
Non-alcoholic fatty liver disease (NAFLD) is an important medical and social problem. Essentially, it can be attributed to the problems of interdisciplinary, since it involves issues related to insulin resistance, metabolic syndrome, dyslipidemia. Due to erased clinical manifestation of nonalcoholic fatty liver disease often is diagnosed at late stages of the disease — fibrosis and cirrhosis. The lack of epidemiological data in Russia has identified the need for a larger study to research the prevalence of NAFLD in the Russian Federation. DIREG 2 was the most extensive epidemiological study on the subject, which is coordinated by the leading experts in partnership with Sanofi Russia.
Objective: to estimate the prevalence of NAFLD within the general practitioner’s and gastroenterologist’s patient flow. It is important to know current prevalence of NAFLD in Novosibirsk (Siberian Federal district) and to compare with DIREG 2 results.
Materials and methods. Epidemiologic, observational, multicenter study assessing the prevalence of NAFLD among patients outpatient practice. A total of 50145 patients (3220 in Novosibirsk) including those suspected of having NAFLD criteria were enrolled in the Program. The investigators were qualified doctors (GPs \ therapist’s \ gastroenterologists), providing outpatient care for the population. The epidemiological data were obtained, recorded during two routine patient visits to investigating centers.
Study results. Percentage of patients with revealed NAFLD within the patient flow primary or consistently coming to selected doctors for any reason including those suspected of having NAFLD was 37.3% in Russia vs 56.9% in Novosibirsk (Siberian Federal district).
1. Babak O. Ya. Suchasna gastroenterologіya. 2010; 4 (54): 8-16.
2. Blinov D. V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2015; 8 (3): 14-19.
3. Blinov D. V., Zimovina U. V., Ushakova T. I. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2015; 1: 31-38.
4. Galimova S. F. RZhGGK. 2012; 22 (3): 38-48.
5. Diagnosis and treatment of nonalcoholic fatty liver disease. Guidelines of the Russian Society for the Study of the Liver. Ed. Acad. Russian Academy of Sciences, prof. VT Ivashkin [Diagnostika i lechenie nealkogol'noi zhirovoi bolezni pecheni. Metodicheskie rekomendatsii Rossiiskogo obshchestva po izucheniyu pecheni. Pod red. akad. RAN, prof. V. T. Ivashkina (in Russian)]. 2015. URL: //rsls.ru/ru/forspecialists/recommendations. Accessed: 12.01.2016.
6. Drapkina O. M., Ivashkin V. T. RZhGGK. 2014; 4: 32-38.
7. Dyadyk A. I. et al. Unіversitets'ka klіnіka. 2013; 9 (2): 236-243.
8. Eremina E. Yu. Arkhiv vnutrennei meditsiny. 2012; 6: 50-54.
9. Zhuravleva L. V. Innovative methods of diagnosis of NAFLD in patients with diabetes. 100 Selected lectures in endocrinology. Ed. YI Karachentseva, AV Kazakova, NA Kravchun, IM Ilyina [Innovatsionnye metody diagnostiki NAZhBP u bol'nykh sakharnym diabetom. 100 Izbrannykh lektsii po endokrinologii. Pod red. Yu.I. Karachentseva, A. V. Kazakova, N. A. Kravchun, I. M. Il'inoi (in Russian)]. Khar'kov. 2015; 2 (2): 42-53.
10. Ivashkin V. T., Maevskaya M. V. Ros zhurn gastroenterol gepatol koloproktol. 2010; 1: 4-13.
11. Ivashkin V. T. et al. Rossiiskie meditsinskie vesti. 2014; 4.
12. Ivashkin V. T., Drapkina O. M., Maev I. V., Trukhmanov A. S., Blinov D. V., Pal'gova L. K., Tsukanov V. V., Ushakova T. I. RZhGGK. 2015; 6: 31-41.
14. Lazebnik L. B., Radchenko V. G., Golovanova E. V., Zvenigorodskaya L. A., Konev Yu. V., Seliverstov P. V., Sitkin S. I., Tkachenko E. I., Ailamazyan E. K., Vlasov N. N., Kornienko E. A., Novikova V. P., Khoroshinina L. P., Zhestkova N. V., Oreshko L. S., Dudanova O. P., Dobritsa V. P., Tur'eva L. V., Tirikova O. V., Kozlova N. M., Eliseev S. M., Gumerov R. R., Ventsak E. V. Nonalcoholic fatty liver disease: clinical features, diagnosis, treatment. Recommendations for physicians. Approved by the Congress of the Scientific Society of Gastroenterologists of Russia (NOHD) 27/05/2015 [Nealkogol'naya zhirovaya bolezn' pecheni: klinika, diagnostika, lechenie. Rekomendatsii dlya terapevtov. Utverzhdeny s»ezdom Nauchnogo obshchestva gastroenterologov Rossii (NOGR) 27.05.2015 (in Russian)].
15. Lipatova L. V. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 20-27.
16. Makarov I. O., Borovkova E. I., Kazakov R. D. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2012; 4: 18-21.
17. Makarov I. O., Pavlov Ch. S., Shemanaeva T. V., Voevodin S. M., Muravei A. Yu. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2013; 1: 22-25.
18. Mamyrbaeva K. M., Mychka V. B., Chazova I. E. Consilium medicum. 2004; 6 (5): 10-12.
19. Nazyrov F. G. Novosti khirurgii. 2013; 21 (4): 45-50.
20. Odinak M. M., Bazilevich S. N., Dyskin D. E., Prokudin M. Yu. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 45-50.
21. Pal'gova L. K. Consilium medicum. Gastroenterologiya. 2014; 1: 18-23.
22. Podymova S. Diseases of the liver. Guidelines for doctors [Bolezni pecheni. Rukovodstvo dlya vrachei (in Russian)]. Moscow. 2005.
23. Polivanov V. A. FARMAKOEKONOMIKA. Sovremennaya farmako eko nomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 1: 7-11.
24. Sas E. I., Blinov D. V., Zimovina U. V. Klinicheskie perspektivy gastroenterologii, gepatologii. 2015; 1: 9-17.
25. Aithal G. P., Das K., Chowdhury A. Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD). GI Epidemiology: Diseases and Clinical Methodology, Second Edition. 2014; 357-372.
26. Armstrong M., Hull D., Guo K. et al. Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in NASH: substudy of a phase 2, randomized placebo-controlled trial. Lancet. 2014; 383: 21.
27. Benda L., Rissel E., Thaler H. Über das histologische Bild der Leberdystrophie und seine Beeinflussung durch agonale und postmortale Vorgänge. Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin. 1957; 330 (6): 594-607.
28. Bugianesi E., Gentilcore E., Manini R. et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2005; 100 (5): 1082-1090.
29. Cave M., Deaciuc I., Mendez C. et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J. Nutr. Biochem. 2007; 18 (3): 184-195.
30. Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatol. 2012; 55 (6): 2005-2023.
31. De Alwis N. M., Day C. P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008; 48 (1): 104-112.
32. Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of nonalcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1. American Journal of Clinical Medicine Research. 2015; 3 (2): 31-36.
33. Festi D., Colecchia A., Sacco T., Bondi M., Roda E., Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004; 5 (1): 27-42.
34. Guerrero R. et al. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology. 2009; 49 (3): 791-801.
35. Gundermann K. J., Kuenker A., Kuntz E., Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011; 63: 643-659.
36. Haring R., Wallaschofski H., Nauck M., Dörr M., Baumeister S. E., Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. Hepatology. 2009; 50:1403-11.
37. Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. United European Gastroenterology Journal. 2015; 3 (1): 344-345.
38. Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. UEG Week 2015. UEG15-ABS-3697.
39. Kistler K. D., Molleston J., Unalp A., Abrams S. H., Behling C., Schwimmer J. B. Symptoms and Quality of Life in Obese Children and Adolescents with Non-alcoholic Fatty Liver Disease Posted: 02/01/2010. Alimentary Pharmacology & Therapeutics. 2010; 31 (3): 396-406.
40. Kuntz E., Kuntz H. D. Hepatology, Principles and practice: history, morphology, biochemistry, diagnostics, clinic, therapy. Springer Science & Business Media. 2006.
41. Lazo M., Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28 (4): 339-50.
42. Loomba R., Cortez-Pinto H. Exercise and improvement of NAFLD: practical recommendations. J. Hepatol. 2015; 63 (1): 10-12.
43. Ludwig J., Viggiano T. R., McGill D. B., Oh B. J. Nonalcoholic steatohepati-tis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-438.
44. Neuschwander-Tetri B. A. Fatty liver and the metabolic syndrome. Curr Opin. Gastroenterol. 2007; 23: 193-198.
45. Neuschwander-Tetri B. A., Loomba R., Sanyal A. J. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 385 (9972): 956-965.
46. Petersen K. F., Dufour S., Befroy D. et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005; 54 (3): 603-608.
47. Pirson M. Why girls love the Dad Bod. Odyssey. 2015. URL: http://theodysseyonline.com/clemson/dad-bod/97484. Data obrashcheniya: 17.02.2016.
48. Ratziu V., Goodman Z., Sanyal A. Current efforts and trends in the treatment of NASH. J. Hepatol. 2015; 62 (1): 65-75.
49. Ryan M. C., Itsiopoulos C., Thodis T. et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J. Hepatol. 2013; 59 (1): 138-143.
50. Targher G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine. 2010; 363 (14): 1341-50.
51. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenome-non? Diabetologia. 2008; 51: 1947-1953.
52. Uygun A., Kadayifci A., Isik A. T. et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2004; 19 (5): 537-544.
53. Von Frerichs F. T. Uber den Diabetes. Berlin. 1884.
54. Westwater J. O., Fainer D. Liver impairment in the obese. Gastroenterology. 1958; 34 (4): 686-693.
55. Zelman S. The liver in obesity. AMA archives of internal medicine. 1952; 90 (2): 141-156.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.